key: cord-0075238-nfflt65u
authors: Agliano, Federica; Karginov, Timofey A.; Ménoret, Antoine; Provatas, Anthony; Vella, Anthony T.
title: Nicotinamide breaks effector CD8 T cell responses by targeting mTOR signaling
date: 2022-02-15
journal: iScience
DOI: 10.1016/j.isci.2022.103932
sha: 18d25d4b83118db7e8e2690d1f6928c22b022b48
doc_id: 75238
cord_uid: nfflt65u

Nicotinamide (NAM) shapes T cell responses but its precise molecular mechanism of action remains elusive. Here, we show that NAM impairs naive T cell effector transition but also effector T cells themselves. Although aerobic glycolysis is a hallmark of activated T cells, CD8(+) T cells exposed to NAM displayed enhanced glycolysis, yet producing significantly less IFNγ. Mechanistically, NAM reduced mTORC1 activity independently of NAD(+) metabolism, decreasing IFNγ translation and regulating T cell transcriptional factors critical to effector/memory fate. Finally, the role of NAM in a biomedically relevant model of lung injury was tested. Specifically, a NAM-supplemented diet reduced systemic IL-2, antigen-specific T cell clonal expansion, and effector function after inhalation of Staphylococcus aureus enterotoxin A. These findings identify NAM as a potential therapeutic supplement that uncouples glycolysis from effector cytokine production and may be a powerful treatment for diseases associated with T cell hyperactivation.

Nicotinamide (NAM) is one of the three forms of vitamin B3, known as a precursor of nicotinamide adenine dinucleotide (NAD + ) ( Bogan and Brenner, 2008; Rajman et al., 2018) . Cellular content of NAM mainly derives from daily diet, such as poultry, beef, and fish; however, a recent study demonstrated gut microbiota as a potential alternative source of NAM for the host (Blacher et al., 2019) . Lastly, NAM can also be formed from NAD + by NAD + -consuming enzymes, such as sirtuins, poly-ADP-ribose polymerases (PARPs), and CD38 (Buque et al., 2021; Rajman et al., 2018) . NAM has been reported to boost NAD + cellular content in several cell types (Hara et al., 2007; Rajman et al., 2018; Yu et al., 2020) . In addition, it is now clear how NAM and other NAD + precursors can aid human health span in different scenarios such as nonmelanoma skin-cancers, systemic inflammation caused by heart failure and prediabetic female obesity (Chen et al., 2015; Rajman et al., 2018; Yoshino et al., 2021; Zhou et al., 2020) , supporting the value of NAM as an efficacious dietary supplement.

Several studies have reported the in vivo anti-inflammatory effect of NAM (Mendez-Lara et al., 2021; Mitchell et al., 2018; Su et al., 2007) . Consistent with these findings, NAM was shown to decrease inflammation and CD4 + T cell infiltration in an Experimental Autoimmune Encephalitis (EAE) model (Kaneko et al., 2006) ; however, recent work demonstrated how NAM enhances T cell response and cytokine production, mediating chemopreventive effects in different models of murine cancers (Buque et al., 2020; Scatozza et al., 2020) . Thus, the role of NAM in T cell-dependent immune responses has been seemingly contradictory. In addition, the molecular mechanism by which NAM shapes T cell function, and whether this is dependent on NAM conversion to NAD + , remains largely unknown (Buque et al., 2021; Rajman et al., 2018) . Thus, given the wide use of NAM as a dietary supplement and the tremendous contribution of T cell-mediated responses in diseases such as infections, cancer, and autoimmune disorders, it is imperative to understand how NAM exactly modulates T cell response and the molecular pathways involved.

Here, the role of NAM in T cells and its underlying mechanism of action were examined. Activated T cells display an enhanced glycolytic metabolism (Warburg effect) and glycolysis regulates IFNg expression at an epigenetic and posttranscriptional level (Chang et al., 2013; Peng et al., 2016) . We show that NAM modulates effector CD8 + T cell metabolism and function, differentially regulating cell glycolytic potential and IFNg release. Specifically, we uncovered a mechanism by which NAM inhibits the mechanistic target of rapamycin complex 1 (mTORC1) pathway, resulting in posttranscriptional control of IFNg, and transcriptional 

Next, we tested if NAM could impact already-differentiated effector CD8 + and CD4 + T cells. Thus, previously differentiated CD8 + T cells in the presence or absence of NAM were restimulated with a-CD3/CD28 beads or with the TCR bypassing mitogen PMAi for 6 h, with or without NAM ( Figure 2A ). Effector CD8 + T cells differentiated without NAM and restimulated with a-CD3/CD28 beads in the presence of NAM, secreted significantly less IFNg, IL-2, IL-5, and IL-6 compared to vehicles ( Figure 2B , left panel). When the same effector CD8 + T cells were restimulated with PMAi, NAM did not have a significant effect on cytokine production ( Figure 2B , right panel). Effector CD8 + T cells previously differentiated in the presence of NAM and restimulated with a-CD3/CD28 beads with NAM, produced significantly less IFNg, IL-2, and IL-5 compared to cells differentiated in the presence of NAM and restimulated with a-CD3/CD28 beads without NAM ( Figure 2C , left panel). Again, PMAi stimulation of cytokine release was not affected by NAM (Figure 2C, right panel) . Of note, cells differentiated with NAM and restimulated without NAM ( Figure 2C , left panel, white bar), upon restimulation, could no longer produce expected levels of cytokines compared to cells differentiated and restimulated without NAM ( Figure 2B , left panel, white bar). Importantly, this shows that NAM can negatively affect future responses of effector CD8 + T cells when it is present at the differentiation stage but not later. Finally, NAM had a weaker effect on CD4 + T cells (Figures S2A and S2B, left panels) , suggesting that effector CD4 + T cells are more resistant to NAM. NAM did not alter PMAi-induced cytokine responses with the exception of increasing IFNg and IL-2 during the restimulation in cells differentiated without NAM ( Figures S2A and 2B , right panels). Thus, NAM significantly impairs the production of several inflammatory cytokines produced by effector CD8 + T cells even when they were fully differentiated in the absence of NAM, which prompted us to study the mechanism of NAM-based IFNg inhibition. Figure 1 . Continued (C) Cell count of negatively selected CD8 + T cells activated in vitro with a-CD3/CD28 beads plus rhIL-2 (30 U/mL) for 66 h, with vehicle or NAM (10 mM). Numbers are given by counting cells before (total cells) and after (live cells) Lympholyte-M gradient. (D) Cell count of negatively selected CD4 + T cells activated in vitro with a-CD3/CD28 beads plus rhIL-2 (30 U/mL) for 66 h, with vehicle or NAM (10 mM). Numbers are given by counting cells before (total cells) and after (live cells) Lympholyte-M gradient. Each dot represents an independent experiment (n = 3-4 mice/experiment). Data are represented as mean G SEM. *p <0.05, N.S. not significant by two-tailed unpaired t test. See also Figure S1 . 

Given that NAM did not affect PMAi stimulation, it was reasoned that its mechanism of action may be TCRdependent. Thus, the widely accepted TCR transgenic OT-I model of SIINFEKL peptide-specific CD8 + T cells was used ( Figure 3A ). Specifically, OT-I CD8 + T cells were adoptively transferred into recipient mice, then immunized the day after with SIINFEKL peptide plus the costimulatory agonists a-CD134/ CD137 mAbs to induce the differentiation of CD8 + effector T cells (Lee et al., , 2007 . These costimulatory pathways drive robust antitumor immunity, and have been associated with various inflammatory diseases such as atherosclerosis (Gotsman et al., 2008; Watts, 2005) . To test the TCR-dependent postulate, day 4 SIINFEKL-primed and costimulated CD8 + T cells were purified and restimulated ex vivo with SIIN-FEKL, PMAi, or three cytokine combinations of IL-2/IL-12 with members of the IL-1 family (IL-33 and IL-36b). These cytokine combinations provide a synergistic signal that induces robust IFNg release in effector T cells, but in a TCR-independent manner (Morales Del Valle et al., 2019; Tsurutani et al., 2016) . This ''innate-like response'' by T cells does not involve TCR activation, and should not be inhibited if NAM is dependent on TCR triggering. As expected, effector CD8 + T cells restimulated with SIINFEKL released significantly less IFNg when NAM was present in culture ( Figures 3B and S3A ), and this was not because of an increased apoptosis ( Figure S3B ). NAM did not affect stimulation by PMAi ( Figure 3C ), but surprisingly, when effector CD8 + T cells were stimulated with cytokine combinations, NAM potently inhibited IFNg release compared to vehicle ( Figure 3D ). Thus, NAM inhibits through TCR-dependent and independent pathways.

It is known that TCR dependent IFNg production by activated CD8 + T cells and the innate-like cytokine receptor IFNg response are both directly coincident with glycolysis (Chang et al., 2013; Tsurutani et al., 2016) . Thus, one reason for NAM-dependent IFNg reduction could be from reduced glycolysis in effector CD8 + T cells. However, effector CD8 + T cells isolated 4 days after adoptive transfer and pretreated for 30 min with NAM, which then remained in the culture for a total of about 3 h, exhibited a significantly higher extracellular acidification rate (ECAR) relative to control cells, resulting in greater glycolytic power ( Figure 3E ). NAM is a precursor of NAD + (Mitchell et al., 2018; Rajman et al., 2018; Tan et al., 2019) , the essential coenzyme involved in redox reactions during glycolysis. Thus, NAM could induce a glycolytic increase in CD8 + T cells because of its conversion to NAD + . Indeed, mass spectrometry analysis revealed that NAM addition resulted in a significant increase of extracellular NAD + ( Figure 3F ). To further confirm that NAD + alone is sufficient to increase glycolysis, exogenous NAD + was added to effector CD8 + T cells for 30 min before ECAR was measured. As hypothesized, cells with NAD + exhibited a significantly higher ECAR compared to control cells ( Figure 3G ). Conversely, blockade of NAD + production from endogenous NAM with the nicotinamide phosphoribosyltransferase (NAMPT) inhibitor FK866, demonstrated that effector CD8 + T cells stimulated with PMAi were no longer able to undergo glycolysis ( Figure 3H ) compared to vehicle. Altogether, these data indicate that NAM significantly enhances effector CD8 + T cell glycolytic power because of its conversion to NAD + , which surprisingly is inversely correlated to IFNg release.

A number of studies have shown that NAM inhibits SIRT1 (Bitterman et al., 2002; Mitchell et al., 2018) , a deacetylase that induces deacetylation of inflammation-related transcription genes (Hwang et al., 2013; Liu and McCall, 2013) . However, NAM can be reconverted to NAD + , which is a SIRT1 activator ( Hwang and Song, 2017) . Furthermore, recent work have shed light on other molecular pathways possibly targeted by NAM (Daniel et al., 2007; Meng et al., 2018; Mouchiroud et al., 2013; Van Gool et al., 2009; Zhang et al., 2021) . However, the mechanism by which NAM reduces cytokine production in T cells is unknown. First, we tested for any SIRT1 involvement in the NAM mechanism of action in CD8 + T cells. Specifically, inhibiting SIRT1 activity using the SIRT1 inhibitor EX-527 did not affect IFNg production in effector CD8 + T cells, even in the presence of NAM ( Figure S4A ), which is expected to block the effect of EX-527 by increasing SIRT1 activity (Hwang and Song, 2017; Jang et al., 2012; Song et al., 2021) . This result suggests that the mechanism by which NAM affects IFNg in CD8 T cells is not necessarily through the activation of SIRT1. Given that NAM significantly reduces IFNg release in effector CD8 + T cells after SIINFEKL restimulation or via the innate-like cytokine receptor response, we reasoned that NAM should affect a pathway that is common between these two immune stimuli. The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that is part of two protein complexes mTORC1 and mTORC2. Although mTORC1 is more involved in protein (including cytokine), lipid, and nucleotide synthesis, mTORC2 plays a main role in survival and proliferation ( Saxton and Sabatini, 2017) , which are all key steps for T cell function. After restimulation with SIIN-FEKL, NAM significantly increased AMPK activity, a mTOR inhibitor, resulting in a reduction of phospho Table S2 ). Next, the downstream mTORC1 target S6 was examined, and consistent with the reduction of p-mTOR, the percentage of p-S6 hi CD8 + T cells was significantly lower when cells Figure S4C ). However, even that modest increase by the cytokines is shut down by NAM, bringing it to a lower level than control (gray bar). Again, the action of PMAi overpowered the inhibitory effect of NAM ( Figure S4B ), suggesting that PMAi is a too strong of an mTORC1 activator (around 70% of the cells are p-S6 hi positive after PMAi restimulation versus 25% seen after SIINFEKL restimulation) which may override any effect induced by NAM. The mTORC1 pathway is involved in protein translation as one of its major functions ( Ma and Blenis, 2009 ). To test if NAM acts by affecting the mTORC1 activity via protein translation, a 3 h post SIINFEKL restimulation was assessed for both release of IFNg protein and for ifng transcription. Thus, effector CD8 + T cells cultured in the presence of NAM exhibited a significant decrease of IFNg release compared to vehicle ( Figure 4E ), whereas early ifng transcription remained unchanged ( Figure 4F ), unlike later time points ( Figure S1B ) which are likely a function of positive feedback by IFNg itself from the vehicle treated effectors. Thus, NAM inhibition of mTOR impairs ifng mRNA translation, not early gene transcription of IFNg.

mTOR is vital to effector/memory CD8 + T cell fate through the regulation of two key transcription factors, T-bet and Eomesodermin. Specifically, although effector CD8 + T cells augment mTOR activity leading to tbet induction and decreasing eomesodermin, memory CD8 + T cells show the opposite effect (Araki et al., 2009; Rao et al., 2010) . To further confirm the NAM-dependent mTOR inhibition, effector CD8 + T cells cultured in the presence of NAM, compared to vehicle, exhibited reduced tbet and increased eomesoderim ( Figures 4G and 4H) . Consistently, NAM also significantly increased the percentage of CD44 + CD62L + CD4 + and CD8 + T cells (memory phenotype) compared to vehicle, without changing the percentage of effector cells (CD44 + CD62L À ) ( Figure S4D ). Thus, NAM might be used to promote memory T cell differentiation.

Next, we tested if the inhibitory effect of NAM on mTORC1 was because of its conversion to NAD + . Without restimulation, the percentage of the p-S6 hi population was even higher in the presence of NAD + . Conversely, when effector CD8 + T cells were restimulated with SIINFEKL for 30 min, the p-S6 hi population in the presence of NAD + was comparable to vehicles. This percentage started to decrease after 60 min (Figure S4E) , suggesting that NAD + can negatively affect S6 phosphorylation only with a longer incubation.

Consistently, the addition of NAD + during restimulation of effector CD8 + T cells significantly reduced IFNg release after 3 h and continued through a time course ( Figure 4I ). However, when NAD + production from endogenous NAM was inhibited by FK866, the IFNg release was not affected ( Figure 4J ), despite FK866 ability to block glycolysis ( Figure 3H ), suggesting that NAD + is not directly involved in the IFNg release in CD8 + T cells. Of note, adding exogenous NAM in the presence of FK866 blockade is not feasible because high concentrations of NAM are an antidote for FK866 action and would reverse inhibition (Hasmann and Schemainda, 2003) . These results indicate that NAD + does not inhibit the mTORC1 pathway directly; rather, its effect at later time points is likely because of the conversion of NAD + into NAM (Rajman et al., 2018). This hypothesis was indeed confirmed because exogenous NAD + resulted in a significantly iScience Article increased extracellular NAM content ( Figure 4K ). To study whether NAM could affect the mTORC2 pathway we looked at one of its downstream molecules, NF-kB (Lee et al., 2010) . With or without SIINFEKL restimulation, NF-kB nuclear translocation was not affected by NAM ( Figure S4F ). All these results indicate that supplemental NAM acts specifically by inhibiting the mTORC1 pathway, resulting in a significant decrease of IFNg mRNA translation. This effect is intrinsically NAM-dependent and is not because of NAM conversion to NAD + .

To dissect the role of exogenous NAM in human T cells, PBMCs samples from healthy donors were used and T cells were activated using a-CD3/CD28 beads for 6 days in the presence of three different doses of NAM. As shown in Figure 5A , NAM significantly reduced IFNg secretion by T cells in a dose-dependent manner without affecting cell viability of CD4 + ( Figure 5B ) and CD8 + T cells ( Figure 5C ). Of note, at the iScience Article highest dose of NAM, both CD4 + and CD8 + T cells significantly reduced CD25 expression compared to control cells ( Figures 5D and 5E ), suggesting impaired IL-2 responsiveness. Consistent with the data from mouse cells, human effector T cells restimulated in the presence of NAM, secreted significantly less IFNg compared to the vehicle ( Figure 5F ). Finally, we enhanced stimulation strength by doubling the bead to cell ratio. Although the middle dose of NAM was now ineffective, the highest dose was still able to decrease IFNg production ( Figure S5A ). Upon restimulation, all the doses significantly reduced IFNg release compared to vehicles ( Figure S5B ). These data show that NAM blocks human T cell effector function and is potentially translatable to controlling human adaptive immune responses.

In recent years, the role of NAM in vivo has been controversial. Two studies demonstrated that NAM mediates chemopreventive effects by boosting immune cell cytokine production in different models of murine cancers (Buque et al., 2020; Scatozza et al., 2020) . Conversely, other studies showed that NAM supplementation reduced inflammation protecting against high fat diet-induced inflammation (Mendez-Lara et al., 2021; Mitchell et al., 2018) , an Experimental Autoimmune Encephalitis (EAE) model (Kaneko et al., 2006) , and pulmonary injury caused by ischemia/reperfusion in rats (Su et al., 2007) .

To dissect the precise role of NAM during in vivo T cell responses we took advantage of S. aureus enterotoxin A, an immunogen that directly activates specific TCR Vb chains (e.g., Vb3) but not Vb14 (Herman et al., 1991) . When delivered intranasally, this model induces acute lung injury (Kumar et al., 2010; Menoret et al., 2018; Svedova et al., 2017) , leading to life threatening complications including diffuse alveolar damage (DAD), acute lung injury (ALI), and acute respiratory distress syndrome (ARDS). Secondly, this response greatly impacts CD8 + T cells and IFNg (Muralimohan et al., 2008) which we have shown are targets for NAM. To recapitulate a typical human scenario, mice were fed a standard diet or one supplemented with NAM for 2 weeks and then intranasally challenged with S. aureus enterotoxin A. During the course of the study, NAM did not alter body weight nor food consumption ( Figures 6A and 6B ). However, 6 h post S. aureus enterotoxin A inhalation the NAM-fed mice exhibited an increased content of serum NAM ( Figure 6C ), coupled with a significant decrease of serum IL-2 compared to control mice ( Figure 6D) . Importantly, the total number and the percentage of S. aureus enterotoxin A responding (TCR Vb3) CD8 + and CD4 + T cells were significantly reduced in peripheral lymph nodes of mice that received the NAM diet ( Figures 6E, 6F, and S6A ). In contrast, the number and the percentage of non-S. aureus enterotoxin A-responding (TCR Vb14) CD8 + and CD4 + T cells were unaffected in the presence of NAM diet ( Figures S6B and  S6C ). Lastly, when cells from peripheral lymph nodes of mice fed with the NAM diet were restimulated in vitro, the number of IFNg-producing CD8 + T cells was significantly reduced compared to control mice, and this included a modest decrease in mean intensity fluorescence ( Figures 6G and 6H) . Altogether, our results show that NAM inhibits T cell clonal expansion and effector cytokine production in vivo, and may inhibit over activation of T cell responses.

In the last decade, the role of metabolic pathways in the regulation of immune responses has emerged, bringing to the rise of a new field called immunometabolism (Makowski et al., 2020; O'Neill et al., 2016; Patel et al., 2019) . Moreover, several studies have shown how specific metabolites are able to regulate T cell function and fate (Okano et al., 2017; Qiu et al., 2019; Tyrakis et al., 2016) . NAM is an immunometabolite known to exert beneficial effects in a variety of biological events, such as aging, oxidative stress and inflammation (Mitchell et al., 2018; Mouchiroud et al., 2013; Tran et al., 2016) . However, the role of NAM on adaptive immune responses has been insufficiently investigated, despite the many reports of its immune altering power. One of the paradigms of immunometabolism is that effector T cells are highly glycolytic and glycolysis is required for effector cytokine production in T cells (Chang et al., 2013; O'Neill et al., 2016) . In this study, we demonstrated that although NAM increases the glycolytic potential of effector CD8 + T cells ( Figure 3E ), it strongly impairs CD8 + T cell differentiation and effector function (Figures 1,  2 , and 3B) via mTORC1 (Figures 4A-4H) and independently of NAD + (Figures 4I-4K) . To the best of our knowledge, this is the first report of a metabolic compound able to boost T cell glycolysis, yet leading to a decrease in T cell effector function. Of note, NAM exerts a potential translatable effect also on human adaptive immunity. In fact, NAM inhibits IFNg and CD25 expression in activated human T cells ( Figure 5 ). Although NAM could affect CD25 expression by inducing CD25 ADP-ribosylation in Tregs (Teege et al., 2015) , activated T cells have been shown to be resistant to ADP-ribosylation of surface protein (Kahl et al., 2000) , leaving the question on how NAM affects CD25 expression in T cells still open. Conversely, other studies demonstrated that NAM mediates chemopreventive effects by boosting T cell response and cytokine production in different models of murine cancers (Buque et al., 2020; Scatozza et al., 2020) and mediates S. aureus clearance in a neutrophil-dependent fashion (Kyme et al., 2012) . Thus, it is likely that the effect of NAM on immune cells can be either inhibitory or stimulatory depending on several factors, such as dose, administration route, and cellular context. Presently, million people are taking NAM dietary supplements to extend life span and prevent aging and inflammation; however, there are still unanswered questions on the function of NAM on immunity. As an example: will NAM supplementation be more valuable before vaccination, or instead will it be more effective in preventing tissue damage such as lung injury? When is the right time to start NAM supplementation? More studies are necessary to avoid unexpected or unwanted outcomes.

Several mechanisms of action have been proposed for NAM in different cell types, suggesting the complexity of its action. NAM was shown to be a SIRT1 inhibitor, facilitating the expansion of hematopoietic progenitors, restoring cognition in Alzheimer's diseases, and ameliorating mouse health span (Green et al., 2008; Mitchell et al., 2018; Peled et al., 2012) . On the contrary, NAM was reported to increase mitophagy because of NAD + content increase and subsequent SIRT1 and AMPK activation in human fibroblasts (Jang et al., 2012; Song et al., 2021) . In mouse hepatocytes, NAM-dependent increase of NAD + induces the activation of the antioxidant gene FOXO, improving metabolic health, and extending life span (Mouchiroud et al., 2013) . In addition, NAM plays an inhibitory role on ROCK/CK1 kinases in human pluripotent stem cells (Meng et al., 2018) , on ERK phosphorylation in B cells (Daniel et al., 2007) , on SIRT6 activity in macrophages and dendritic cells (Van Gool et al., 2009) , and on MAPK and NF-kB activity in macrophages (Zhang et al., 2021) . In this study, we show that the molecular mechanism by which NAM reduces IFNg in CD8 + effector T cells is dependent on the mTORC1 pathway through AMPK activation ( Figures 4A-4D) .

It is well known that AMPK activation can be triggered by an increase of AMP/ADP ratio or a Ca 2+ increase ( Shackelford and Shaw, 2009 ). Here we show that SIRT1 is not involved in the NAM-dependent IFNg decrease in CD8 T cells; thus, it is possible that in these cells AMPK is activated by other mechanisms. However, more studies are needed to better understand the molecular mechanism by which NAM induces AMPK activation in CD8 + T cells. Consistent with mTORC1 involvement in protein synthesis ( Saxton and Sabatini, 2017) , NAM-dependent mTORC1 inhibition leads to a significant decrease of IFNg translation in effector CD8 + T cells ( Figures 4E and 4F ). However, NAM eventually affects IFNg transcription at later time points ( Figure S1C ), which is probably because of an IFNg-driven feedback loop. mTOR determines T cell effector/memory fate through transcriptional regulation of tbet and eomesodermin (Araki et al., 2009; Rao et al., 2010) . We found that NAM-associated mTOR inhibition reduces tbet and enhances eomesodermin transcription ( Figures 4G and 4H ), suggesting a potential use of NAM in generating memory T cells. Furthermore, our work shows that the inhibitory effect of NAM on mTORC1 is not dependent on NAD + , pointing out the intrinsic biological relevance of NAM, which therefore does not act only as a NAD + booster (Rajman et al., 2018) .

S. aureus enterotoxin A is a superantigen that activates specific TCR Vb T cells (Herman et al., 1991) and induces acute lung injury (Kumar et al., 2010; Li et al., 2020; Menoret et al., 2018; Svedova et al., 2017) , exerting a major effect on CD8 + T cells infiltration and IFNg production (Muralimohan et al., 2008) . Other studies have addressed the effect of NAM in innate immune and inflammatory responses against acute lung injury (Su et al., 2007; Zhang et al., 2021) . However, the role of NAM on the adaptive arm is completely unknown. In this study, we have used S. aureus enterotoxin A as a model of direct T cell response in vivo. A NAM supplementation reduces S. aureus enterotoxin A-specific CD4 + and CD8 + T cell expansion and serum IL-2 in vivo, and decreases the ability of effector CD8 + T cell population to produce IFNg in response to a second stimulation with S. aureus enterotoxin A (Figures 6 and S6 ). Overall, our study reveals an inhibitory effect of NAM on CD8 + T cell differentiation and effector function. Thus, NAM supplementation could potentially prevent the development of diseases associated with T cell hyperactivation, and ameliorate the prognosis in hospitalized patients. Importantly, NAM would not wipe out the entire CD8 + T cell response which is needed to restrain the virus outside of the lung and also to fight coinfections. iScience Article that NAM induces the expression of memory markers in T cells; however, more studies should be performed to better dissect the role of NAM on memory T cell differentiation and function in vivo.

Detailed methods are provided in the online version of this paper and include the following: 

We are thankful to Drs. Rachel Page and Vijay Rathinam for their critical reading of the manuscript and valuable feedback. This work was supported in part by NIH grants P01AI056172 and R21AI139891, institutional support, and Boehringer Ingelheim endowed Chair in Immunology.

A.T.V. and F.A. conceived and designed the experiments. F.A., T.A.K., and A.M. performed the experiments and data analysis. A.P. performed the UHPLC-QTOF HRMS analysis. F.A. drafted the manuscript. A.M. and T.A.K. reviewed the manuscript. A.T.V. supervised the study and finalized the manuscript. All authors read and approved the final manuscript. 

T-cell differentiation

Nicotinamide treatment

Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition

Possible mechanisms of cancer prevention by nicotinamide

Nicotinamide inhibits B lymphocyte activation by disrupting MAPK signal transduction

Spontaneously resolving joint inflammation is characterised by metabolic agility of fibroblast-like synoviocytes

T-cell costimulation and coinhibition in atherosclerosis

Superantigens: mechanism of T-cell stimulation and role in immune responses

Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic

Nicotinamide-induced mitophagy: event mediated by high NAD+/NADH ratio and SIRT1 protein activation

Metalloprotease-mediated shedding of enzymatically active mouse ecto-ADPribosyltransferase ART2.2 upon T cell activation

Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models

Rapid alphabeta T-cell responses orchestrate innate immunity in response to Staphylococcal enterotoxin A

The systemic and pulmonary immune response to staphylococcal enterotoxins

C/EBPepsilon mediates nicotinamideenhanced clearance of Staphylococcus aureus in mice

Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways

OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function

CD134 costimulation couples the CD137 pathway to induce production of supereffector CD8 T cells that become IL-7 dependent

Acute lung injury in patients with COVID-19 infection

Deacetylation by SIRT1 reprograms inflammation and cancer

Analysis of relative gene expression data using real-time quantitative PCR and the 2

Molecular mechanisms of mTOR-mediated translational control

Immunometabolism: from basic mechanisms to translation

Nicotinamide protects against diet-induced body weight gain, increases energy expenditure, and induces white adipose tissue beiging

Nicotinamide promotes cell survival and differentiation as kinase inhibitor in human pluripotent stem cells

T cell-directed IL-17 production by lung granular gammadelta T cells is coordinated by a novel IL-2 and IL-1beta circuit

Nicotinamide improves aspects of healthspan, but not lifespan, in mice

Costimulation induces CD4 T cell antitumor immunity via an innate-like mechanism

The NAD(+)/Sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling

Inhalation of Staphylococcus aureus enterotoxin A induces IFN-gamma and CD8 T cell-dependent airway and interstitial lung pathology in mice

Glycolytic reprogramming of macrophages activated by NOD1 and TLR4 agonists: No association with proinflammatory cytokine production in normoxia

A guide to immunometabolism for immunologists

bromopyruvate ameliorate autoimmune arthritis by modulating Th17/Treg cell differentiation and suppressing dendritic cell activation

mTOR signaling in growth, metabolism, and disease

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

Nicotinamide treatment facilitates mitochondrial fission through Drp1 activation mediated by SIRT1-induced changes in cellular levels of cAMP and Ca

Nicotinamide abrogates acute lung injury caused by ischaemia/reperfusion

Therapeutic blockade of CD54 attenuates pulmonary barrier damage in T cell-induced acute lung injury

Nicotinamide metabolism modulates the proliferation/differentiation balance and senescence of human primary keratinocytes

Tuning IL-2 signaling by ADP-ribosylation of CD25

PGC1alpha drives NAD biosynthesis linking oxidative metabolism to renal protection

Costimulation endows immunotherapeutic CD8 T cells with IL-36 responsiveness during aerobic glycolysis

S-2-hydroxyglutarate regulates CD8(+) T-lymphocyte fate

Nicotinamide is a potent inhibitor of proinflammatory cytokines

Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner

TNF/TNFR family members in costimulation of T cell responses

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

Disturbed mitochondrial dynamics in CD8(+) TILs reinforce T cell exhaustion

The mechanism of nicotinamide on reducing acute lung injury by inhibiting MAPK and NF-kappaB signal pathway

Nicotinamide reduces renal interstitial fibrosis by suppressing tubular injury and inflammation

Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure

NH) plus 10 mg of a-CD137 (clone 3H3

Cells were then restimulated using SIINFEKL, PMAi or IL-2/IL-12 plus IL-33 or IL-36b (R&D Systems, Minneapolis, MN) mononuclear cells (PBMCs) (STEMCELL Technologies, Vancouver, Canada) from male healthy donors (25-32 years old) were cultured at 2.25 3 10 6 cells/ml in complete T cell media: RPMI 1640 (ATCC 30-2001), 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4500 mg/L glucose, and 1500 mg/L sodium bicarbonate, 1x antibiotic-antimycotic (Gibco), 1x non-essential amino acids (Gibco) and 10 ng/ml recombinant human IL-2 (R&D Systems

Serum was collected 6 h post immunization. Mice continued on the control and NAM supplemented diet for two more days, and then sacrificed. Axillary and brachial lymph nodes (LN) were collected and the isolated LN cells were analyzed by flow cytometry

For phospho (p) S6 detection, cells were washed with FACS buffer and further processed for intracellular staining using the Foxp3 fixation/permeabilization buffer (eBioscience, Waltham, MA) as per the manufacturer's instructions. The fixed and permeabilized cells were then incubated with the Phospho-S6 (Ser235, Ser236) antibody from ThermoFisher Scientific (Waltham, MA) and diluted in 1x permeabilization buffer overnight at 4 C. For IFNg detection, cells were washed with FACS buffer

All primers are listed in Table S1. Each sample was run in duplicate and gene expression levels were normalized to b-actin as housekeeping gene

CA) as per manufacturer's instructions. Data were collected on the ZE5 Cell analyzer

MA) for nuclear and cytoplasmic extractions, according to the manufacturer's instructions. Lysates were resuspended in Laemmli buffer (50 mm Tris-Cl, pH 6.8, 10% glycerol, 2% SDS, 0.1% bromophenol blue, 5% 2-mercaptoethanol), boiled for 5 min

Extracellular acidification rates (ECAR) were measured using an XF-96 extracellular flux analyzer and a glycolysis stress test kit as per the manufacturer's instructions (Agilent

measurement Samples were agitated and 100 mL of each sample (including quality control samples) were measured and spiked with 5 mL internal standard solution followed by the addition of 100 mL of 70:30 cold ethanol/water. Samples were vortexed for 10 min at 2,500 RPM and centrifuged for 10 min at 14,000 RPM. The collected supernatant was transferred to an analytical vial and analyzed by UHPLC-QTOF HRMS. Quality control and actual samples were analyzed using a Sciexâ Exion UHPLC coupled with an Sciexâ X500Rä Quadrupole/ Time of Flight (AB Sciex

The detection and quantification of analytes and internal standard were performed in positive ESI + MRMHRä mode. The Sciexâ OS software was utilized for guided analyte signal optimization. Statistical analysis for obtaining calibration and quantification results for all compounds was performed using Analyticsä

The authors declare no competing financial interests. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Anthony T. Vella (vella@uchc.edu).

This study did not generate new unique reagents.

Data reported in this paper will be shared by the lead contact upon request. This paper does not report original code. Additional information and data reported in this paper is available from the lead contact upon request.

Male and female C57BL/6J mice (6-9 weeks old) were purchased from the Jackson Laboratory (Bar Harbor, ME). CD45.1 + RAG À/À OT-I TCR transgenic mice were bred in-house. All mice were maintained in the UConn Health animal facility. All animal procedures were approved by the UConn Health Institutional Animal Care and Use Committee and performed in accordance with National Institutes of Health Animal Care and Use Guidelines. Spleen and lymph node preparations from CD45.1 + RAG À/À OT-I transgenic mice containing 5 3 10 5 CD8 + T cells expressing T cell receptor Va2 Vb5 and specific to Ova peptide SIIN-FEKL were adoptively transferred into CD45.2 + C57BL/6J mice. The following day, recipients were immunized intraperitoneally (i.p.) with 50 mg SIINFEKL peptide (InvivoGen, San Diego, CA) and 20 mg a-CD134

Oligonucleotides Primers for qPCR, see Table S1 see